Publication NumberUS 10149898
Assignees
  • TAIGA BIOTECHNOLOGIES, INC.
Filing StatusIssued Patent
US PAIR StatusPatented Case
US PAIR Status Date2018-11-20
Application Number15/668451
AvailabilityUnknown
Filing Date2017-08-03
Publication Date2018-12-11

Abstract

Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).

Claims

  • 1. A method for treating a melanoma in a recipient subject, comprising administering one or more modified immune cells to the recipient subject in need thereof, wherein the one or more modified immune cells: (a) comprise a MYC fusion peptide comprising (i) a protein transduction domain and (ii) a MYC polypeptide sequence, wherein the MYC fusion peptide comprises SEQ ID NO: 1; (b) are reactive to a tumor-specific antigen; and (c) are derived from primary immune cells isolated from a donor subject having a melanoma.
  • 2. The method of claim 1, wherein the donor subject and the recipient subject are the same.
  • 3. The method of claim 1, donor subject and the recipient subject are different.
  • 4. The method of claim 1, wherein the one or more modified immune cells are prepared by contacting the primary immune cells in vitro with the MYC fusion peptide following isolation.
  • 5. The method of claim 4, further comprising expanding the primary immune cells in vitro prior to and/or following contacting the primary immune cells with the MYC fusion peptide.
  • 6. The method of claim 1, wherein the protein transduction domain sequence is a TAT protein transduction domain sequence.
  • 7. The method of claim 1, wherein the one or more modified immune cells have antitumor activity against melanoma cells in the recipient subject.
  • 8. The method of claim 1, wherein the one or more modified immune cells comprises a T cell, a B cell, an NK, or any combination thereof.
  • 9. The method of claim 1, wherein method further comprises isolating the primary immune cells from the donor subject.
  • 10. The method of claim 1, wherein the one or more modified immune cells are administered intravenously, intraperitoneally, subcutaneously, intramuscularly, or intratumorally.
  • 11. The method of claim 1, further comprising lymphodepleting the subject prior to administration of the one or more modified immune cells.
  • 12. The method of claim 1, wherein the melanoma is metastatic.
  • 13. The method of claim 1, wherein the subject is a human or a non-human animal.